[HTML][HTML] Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate …
PW Kantoff, TJ Schuetz, BA Blumenstein… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, M Wyand, K Manson…
Journal of Clinical Oncology, 2010•ncbi.nlm.nih.govPurpose Therapeutic prostate-specific antigen (PSA)–targeted poxviral vaccines for prostate
cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for
prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized,
controlled, and blinded phase II study.
cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for
prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized,
controlled, and blinded phase II study.
Abstract
Purpose
Therapeutic prostate-specific antigen (PSA)–targeted poxviral vaccines for prostate cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized, controlled, and blinded phase II study.
ncbi.nlm.nih.gov